We therefore hypothesized that combined administration of anti-osteopontin antibody in the early acute phase (4 h) with that in the late acute phase (15 h) post-stroke, when the osteopontin levels peak might lead to a more significant therapeutic benefit including improvement of infarct volumes along with improvement of edema and neurological outcome. This evidence concerns the gene SPP1 and Stroke.